Back to Search Start Over

Time-to-Event Genome-Wide Association Study for Incident Cardiovascular Disease in People with Type 2 Diabetes Mellitus.

Authors :
Kwak SH
Hernandez-Cancela RB
DiCorpo DA
Condon DE
Merino J
Wu P
Brody JA
Yao J
Guo X
Ahmadizar F
Meyer M
Sincan M
Mercader JM
Lee S
Haessler J
Vy HMT
Lin Z
Armstrong ND
Gu S
Tsao NL
Lange LA
Wang N
Wiggins KL
Trompet S
Liu S
Loos RJF
Judy R
Schroeder PH
Hasbani NR
Bos MM
Morrison AC
Jackson RD
Reiner AP
Manson JE
Chaudhary NS
Carmichael LK
Chen YI
Taylor KD
Ghanbari M
van Meurs J
Pitsillides AN
Psaty BM
Noordam R
Do R
Park KS
Jukema JW
Kavousi M
Correa A
Rich SS
Damrauer SM
Hajek C
Cho NH
Irvin MR
Pankow JS
Nadkarni GN
Sladek R
Goodarzi MO
Florez JC
Chasman DI
Heckbert SR
Kooperberg C
Dupuis J
Malhotra R
de Vries PS
Liu CT
Rotter JI
Meigs JB
Source :
MedRxiv : the preprint server for health sciences [medRxiv] 2023 Jul 28. Date of Electronic Publication: 2023 Jul 28.
Publication Year :
2023

Abstract

Background: Type 2 diabetes mellitus (T2D) confers a two- to three-fold increased risk of cardiovascular disease (CVD). However, the mechanisms underlying increased CVD risk among people with T2D are only partially understood. We hypothesized that a genetic association study among people with T2D at risk for developing incident cardiovascular complications could provide insights into molecular genetic aspects underlying CVD.<br />Methods: From 16 studies of the Cohorts for Heart & Aging Research in Genomic Epidemiology (CHARGE) Consortium, we conducted a multi-ancestry time-to-event genome-wide association study (GWAS) for incident CVD among people with T2D using Cox proportional hazards models. Incident CVD was defined based on a composite of coronary artery disease (CAD), stroke, and cardiovascular death that occurred at least one year after the diagnosis of T2D. Cohort-level estimated effect sizes were combined using inverse variance weighted fixed effects meta-analysis. We also tested 204 known CAD variants for association with incident CVD among patients with T2D.<br />Results: A total of 49,230 participants with T2D were included in the analyses (31,118 European ancestries and 18,112 non-European ancestries) which consisted of 8,956 incident CVD cases over a range of mean follow-up duration between 3.2 and 33.7 years (event rate 18.2%). We identified three novel, distinct genetic loci for incident CVD among individuals with T2D that reached the threshold for genome-wide significance ( P <5.0×10 <superscript>-8</superscript> ): rs147138607 (intergenic variant between CACNA1E and ZNF648 ) with a hazard ratio (HR) 1.23, 95% confidence interval (CI) 1.15 - 1.32, P =3.6×10 <superscript>-9</superscript> , rs11444867 (intergenic variant near HS3ST1 ) with HR 1.89, 95% CI 1.52 - 2.35, P =9.9×10 <superscript>-9</superscript> , and rs335407 (intergenic variant between TFB1M and NOX3 ) HR 1.25, 95% CI 1.16 - 1.35, P =1.5×10 <superscript>-8</superscript> . Among 204 known CAD loci, 32 were associated with incident CVD in people with T2D with P <0.05, and 5 were significant after Bonferroni correction ( P <0.00024, 0.05/204). A polygenic score of these 204 variants was significantly associated with incident CVD with HR 1.14 (95% CI 1.12 - 1.16) per 1 standard deviation increase ( P =1.0×10 <superscript>-16</superscript> ).<br />Conclusions: The data point to novel and known genomic regions associated with incident CVD among individuals with T2D.

Details

Language :
English
Database :
MEDLINE
Journal :
MedRxiv : the preprint server for health sciences
Accession number :
37546893
Full Text :
https://doi.org/10.1101/2023.07.25.23293180